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Gastrointestinal stromal tumors (GISTs) in adults are generally driven by somatic gain-of-
function mutations in KIT or PDGFRA, and biological therapies targeted to these receptor
tyrosine kinases comprise part of the treatment regimen for metastatic and inoperable
GISTs. A minority (10–15%) of GISTs in adults, along with ∼85% of pediatric GISTs, lacks
oncogenic mutations in KIT and PDGFRA. Not surprisingly these wild type (WT) GISTs
respond poorly to kinase inhibitor therapy. A subset of WT GISTs shares a set of distin-
guishing clinical and pathological features, and a flurry of recent reports has convincingly
demonstrated shared molecular characteristics.These GISTs have a distinct transcriptional
profile including over-expression of the insulin-like growth factor-1 receptor, and exhibit
deficiency in the succinate dehydrogenase (SDH) enzyme complex. The latter is often but
not always linked to bi-allelic inactivation of SDH subunit genes, particularly SDHA. This
review will summarize the molecular, pathological, and clinical connections that link this
group of SDH-deficient neoplasms, and offer a view toward understanding the underlying
biology of the disease and the therapeutic challenges implicit to this biology.
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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are the most common
sarcomas of the digestive tract, with an estimated annual incidence
of 11–19.6 cases per million (Corless et al., 2011). GISTs generally
present as sporadic disease in older adults, with a median age of
diagnosis of 63 and 59 years in two large series of GISTs presenting
in the stomach and small intestine, respectively (Miettinen et al.,
2005b, 2006b). In these reports from the Armed Forces Institute of
Pathology, civilian-only GIST cases are relatively gender-balanced,
with a male to female ratio of 48.7:51.3% (n= 2109). Though
GISTs occur throughout the GI tract, by far the most common
sites are in the stomach (60%) and intestine (30%) (Demetri et al.,
2010). These predominantly spindle-cell tumors are thought to
originate from the interstitial cells of Cajal (ICC), which pro-
mote the autonomous peristaltic contractions of the gut. GISTs
and ICC share morphological and immunophenotypic character-
istics, most notably the expression of the KIT receptor tyrosine
kinase (RTK) (Kindblom et al., 1998; Sircar et al., 1999). At the
molecular level, 85–90% of GISTs possess mutually exclusive gain-
of-function mutations in KIT or in the related RTK PDGFRA
(Hirota et al., 1998, 2003; Rubin et al., 2001; Heinrich et al., 2003),
while ∼10–15% lack these kinase mutations and are known as
wild type (WT) GIST. Secondary large-scale cytogenetic changes,
such as loss of chromosome 14q, 22q, and 1p, occur frequently
in the progression of mutant GIST (El-Rifai et al., 2000a; Debiec-
Rychter et al., 2001; Assamaki et al., 2007; Gunawan et al., 2007;
Wozniak et al., 2007). Mutations in KIT occur most frequently
in exon 11, encoding the juxtamembrane domain of the recep-
tor, or in exon 9, which encodes the extracellular dimerization
domain, while mutations in the tyrosine kinase domain (exon 18)
is the most common PDGRA event (Corless et al., 2011). Recently,
mutations in the serine-threonine protein kinase BRAF have also
been reported as rare events in GIST (Agaram et al., 2008b; Agaimy
et al., 2009; Belinsky et al., 2009; Hostein et al., 2010; Corless et al.,
2011). Treatment for advanced GIST has been greatly enhanced
by the tyrosine kinase inhibitors (TKI) imatinib mesylate (IM;
Gleevec, Novartis) and sunitinib (Sutent, Pfizer), which target the
constitutively active mutant isoforms of KIT and PDGFRA.
Gastrointestinal stromal tumors are exceedingly rare in chil-
dren and adolescents. In the two large series mentioned above,
GIST patients under 21 years of age constituted only 2.7% of gas-
tric and 0.6% of intestinal GIST cases (Miettinen et al., 2005b,
2006b). The United Kingdom National Registry of Childhood
Tumors reported an annual incidence of 0.02 per million for chil-
dren under the age of 14 (Benesch et al., 2009). Pediatric GISTs
exhibit distinct clinical, pathological, and molecular characteris-
tics as compared to adult tumors. GISTs in this age group occur
more often in girls, generally present in the stomach as multi-
focal nodular growth, and usually lack activating kinase mutations
and cytogenetic aberrations seen in adult GISTs (Janeway et al.,
2007; Agaram et al., 2008a; Belinsky et al., 2009; Benesch et al.,
2009; Pappo and Janeway, 2009). Pediatric and adult WT GISTs
express high levels of another RTK, the insulin-like growth factor-
1 receptor (IGF1R) (Prakash et al., 2005; Agaram et al., 2008a; Tarn
et al., 2008; Janeway et al., 2010), which may represent an alternate
therapeutic target in this subset of GISTs.
A subset of adult WT GISTs shares the distinct clinico-
pathological and molecular characteristics of pediatric tumors;
these tumors are sometimes described as “Type II” or “pediatric-
like” GISTs to delineate them from the majority of adult sporadic
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tumors (Gill et al., 2010b; Rege et al., 2011). Included under
this umbrella classification are GISTs from multi-neoplastic syn-
dromes known as Carney triad (CT) and Carney–Stratakis syn-
drome (CSS). The unifying molecular observation for this group
of tumors was recently shown to be a deficiency in the mitochondr-
ial succinate dehydrogenase (SDH) complex, often but not always
attributable to inactivating mutations in SDH component genes
(Gill et al., 2010b; Gaal et al., 2011; Janeway et al., 2011; Miettinen
et al., 2011; Belinsky et al., 2012; Doyle et al., 2012). The mitochon-
drially located SDH complex oxidizes succinate to fumarate within
the Krebs/tricarboxylic acid (TCA) cycle and passes electrons gen-
erated in this reaction along to the electron transport chain. In this
review we will explore the recent evolution in our understanding
of the underlying genetics and biology of SDH-deficient GISTs,
and discuss treatment implications for these patients.
CLINICAL FEATURES OF GISTs IN THE PEDIATRIC
POPULATION
Gastrointestinal stromal tumor in children typically presents in
the second decade of life (median age of 13 years) with a strong
predilection toward females, who represent∼70–75% of sporadic
pediatric cases (Benesch et al., 2009; Pappo and Janeway, 2009;
Rink and Godwin, 2009). This gender bias seems to be devel-
opmentally related: in a series of 44 pediatric and young adults
(5–21 years) with GIST originating in the stomach, essentially
all patients under 16 years of age were girls (24/25, 96%), while
the post-pubertal gender imbalance was less pronounced (11/19
females, 58%) (Miettinen et al., 2005a). In non-biased sample sets
the main site of presentation is gastric (∼75%), and these tumors
are more often of epithelioid or mixed epithelioid/spindled cell
morphology, in contrast to the adult form in which spindle-cell
morphology predominates (Benesch et al., 2009). Pediatric GIST
often presents with multi-focal nodular growth (Kerr et al., 1999;
Prakash et al., 2005; Agaram et al., 2008a), which is rarely seen in
adult sporadic cases. In addition, lymph node involvement is seen
more often than in adult GIST, often in association with metasta-
tic disease to liver and abdominal sites (Kerr et al., 1999; Agaram
et al., 2008a; Miettinen et al., 2011). The natural history of these
tumors nevertheless appears to be more indolent than adult GISTs,
as patients can survive for many years with metastatic disease
(Miettinen et al., 2005a). Interestingly, many of the characteris-
tics of GISTs in the pediatric population (e.g., female predilection,
predominance of gastric, multi-focal tumors of epithelioid mor-
phology) are not as clearly defined in the more heterogeneous
group of young adult (i.e., 21–30 years) GIST patients (Miettinen
et al., 2005a; Prakash et al., 2005; Agaram et al., 2008a; Rink and
Godwin, 2009), suggesting that some but not all of the patients in
this age group may more properly be considered with the pediatric
group.
The hallmarks of early onset multi-focal disease with a strong
predilection for females are suggestive of a cancer pre-disposition
syndrome. A summary of some of the characteristics of several
described GIST syndromes is shown in Table 1. Familial GIST
Syndrome (FGS), seen in ∼20 kindreds, is an autosomal dom-
inant GIST tumor syndrome associated with germline KIT or
PDGFRA mutations (Agarwal and Robson, 2009). FGS-associated
GISTs resemble the sporadic kinase-mutant forms in terms of
gender balance, anatomic distribution, and prevalence of spindle-
cell morphology. GISTs occurring in the context of the autoso-
mal dominant disorder neurofibromatosis type 1 (NF1, OMIM
162200), while generally WT for KIT and PDGFRA, typically
present in the small bowel and possess spindle-cell morphology
(Andersson et al., 2005; Miettinen et al., 2006a). GISTs in these
patients also tend to manifest later in life, and these patients
manifest the cutaneous and ocular findings associated with NF1
in addition to their pre-disposition for GISTs and various ner-
vous system tumors. However, pediatric GISTs share a number
of features with GISTs of the CT. CT, first described in 1977
(Carney et al., 1977) and subsequently reviewed in larger case
series (Carney, 1983, 1999), is the non-familial association of gas-
tric GISTs, functioning extra-adrenal paraganglioma (PGL), and
pulmonary chondromas (OMIM 604287). Recently, esophageal
leiomyomas and adrenal cortical adenomas have been added as
components of the syndrome (Carney, 1999; Knop et al., 2006).
Approximately 88% of CT patients are female with onset in the
majority of patients before the age of thirty (Zhang et al., 2010).
As with the pediatric patients with non-syndromic GIST, CT in
males is generally seen in post-pubertal patients (Carney, 1983;
Matyakhina et al., 2007). The GIST component of the triad pre-
dominately arises in the stomach and typically lacks detectable KIT
and PDGFRA mutations. These and other shared characteristics
(e.g., epithelioid morphology, chronic yet indolent clinical course)
suggest a strong connection between sporadic pediatric GISTs and
those associated with the triad. Indeed, the long interval (mean
∼8 years) (Carney, 2009) between detection of the first and sec-
ond components of the CT imply that some apparently sporadic
cases of pediatric GIST may actually be formes frustes of the triad.
The coincidental occurrence of three uncommon tumors in
young females suggested an etiological connection in the CT cases.
The family histories of 79 patients with two or three of the associ-
ated tumors was examined (357 close relatives),only two cases with
a familial connection were identified, indicating the triad is not
Table 1 | Characteristics of syndromic GISTs.
Syndrome Carney triad Carney–Stratakis Familial GIST NF1-related
Median age (years) 18 19 40–50 49
Gender predilection Female>male None None None
Germline mutations Unknown SDHB-D KIT, PDGFRA NF1
Inheritance Not inherited Autosomal dominant Autosomal dominant Autosomal dominant
Anatomic distribution Gastric Gastric Gastric, small bowel Small bowel
GIST histology Epithelioid/mixed Epithelioid/mixed Spindle-cell Spindle-cell
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inherited (Carney, 1999). Two patients with an incomplete presen-
tation of gastric GISTs and PGL each had a sibling with multi-focal
PGL. In a subsequent study Carney and Stratakis detailed a familial
association of gastric stromal sarcomas (or GISTs) and PGLs in 12
patients (7 male and 5 female, average age 22 years) from five kin-
dreds, including the original two sibships (Carney and Stratakis,
2002). In patients with the dyad of familial PGL and gastric GISTs,
or CSS (OMIM 606864), the inheritance pattern appears to be
autosomal dominant, albeit with incomplete penetrance. Familial
PGL syndromes had long been documented (Chase, 1933; Chedid
and Jao, 1974), however beginning in the 1990s linkage studies
were able to map these syndromes to specific chromosomal loci
(Heutink et al., 1992; Mariman et al., 1995; Niemann et al., 2001),
and subsequently these syndromes were linked to germline muta-
tions in component genes of the SDH complex (see Discussion
below). In turn, germline SDHB, SDHC, or SDHD mutations were
identified in the CSS families with the dyad of GIST and PGL,
establishing the genetic basis of the disease (McWhinney et al.,
2007; Pasini et al., 2008). These mutations have not been identi-
fied in the non-familial CT patients (Zhang et al., 2010). Recently,
immunohistochemistry for the detection of an intact SDH com-
plex has been used to triage genetic SDH deficiency in PGL, and
utilized by groups working in the GIST field to solidify the involve-
ment of the SDH complex in the oncogenesis of pediatric and
syndromic GISTs, as well as a subset of adult WT GISTs. A flurry
of recent reports has identified an important role for SDHA gene
inactivation in SDH–deficient GIST.
SDH DEFICIENCY IN GIST AND IN ASSOCIATED TUMORS
Both CT and CSS cases manifest the association of gastric GIST
with extra-adrenal PGLs, so it is reasonable to suspect a shared
etiology between these tumors in some cases. PGLs are highly vas-
cularized tumors originating from neural crest-derived chromaffin
cells. PGLs, along with pheochromocytomas (PHEOs) originat-
ing in the adrenal gland, are rare tumors, with an estimated
annual incidence of 2–10 per million. As with GIST, most of these
tumors occur sporadically, however up to 30% of these tumors
may be inherited in a number of syndromes associated with spe-
cific gene mutations (Welander et al., 2011). PGLs and PHEOs,
along with GISTs, are found in association with the autosomal
dominant NF1 syndrome. However, as mentioned previously,
NF1-asociated GISTs do not exhibit the clinico-pathological and
demographic characteristics of CT and pediatric GISTs. Multiple
endocrine neoplasia type 2 (MEN2, OMIM 171400), associated
with PHEOs, medullary thyroid carcinoma, and other manifes-
tations, is linked to gain-of-function mutations in the RET gene
(Mulligan et al., 1993; Hofstra et al., 1994). RET encodes an RTK
that plays an important role in neural crest development. Von
Hippel–Lindau syndrome (OMIM 193300) is an autosomal dom-
inant disorder that pre-disposes toward central nervous system
and retinal hemangioblastomas, renal cell carcinomas, pancre-
atic tumors, along with PGL/PHEO and other manifestations.
Germline and somatic bi-allelic mutations in the VHL gene serve
to inactivate this tumor suppressor gene, which is involved in
turnover of the hypoxia-inducible factors (HIF), part of the cel-
lular transcription factor complex that responds to low oxygen
(hypoxic) conditions (see Discussion below). To our knowledge
RET and VHL mutations have not been reported in GIST,although
several recent studies have looked for mutations in these genes
in individual cases (Bano et al., 2012; Boguszewski et al., 2012).
More recently, germline mutations in the transmembrane protein
TMEM127 and in the transcription factor MAX (MYC associated
factor X) have been linked to PHEOs and a few PGLs (Qin et al.,
2010; Comino-Mendez et al., 2011; Welander et al., 2011). In the
last decade, however, the involvement of the SDH complex in a
number of hereditary PGL syndromes was clearly established, and
in turn SDH deficiency was implicated in the oncogenesis of a
subset of WT GIST.
Germline mutations in SDHD (Baysal et al., 2000), SDHC
(Niemann and Muller, 2000), and SDHB (Astuti et al., 2001) are
associated with the familial PGL/PHEO syndromes PGL1 (OMIM
16800), PGL2 (OMIM 601650), and PGL4 (OMIM 115310),
respectively. More recently the PGL2 syndrome has been attributed
to mutations in an assembly factor for the SDH complex, SDHAF2
(Hao et al., 2009). In a recent development particularly relevant to
the pathogenesis of SDH-deficient GISTs, a heterozygous germline
SDHA mutation, accompanied by somatic loss-of-heterozygosity
(LOH) in the 5p15 region surrounding SDHA was identified in a
single PGL case (Burnichon et al., 2010). A second report identi-
fied mutations in this SDH gene in five additional PGLs among a
group of 316 PGLs and PHEOs, including 129 apparently sporadic
cases (Korpershoek et al., 2011). Deleterious mutations in any of
these genes that result in loss of SDH catalytic activity have been
shown to result in loss of expression of the SDHB protein (Douwes
Dekker et al., 2003; Dahia et al., 2005). This phenomenon led to
the development of a sensitive and specific approach to triage SDH
deficiency based on negative immunohistochemical staining of the
SDHB subunit (van Nederveen et al., 2009; Gill et al., 2010a). The
utilization of SDHB IHC to identify SDH complex deficiency has
recently been extended to the study of pediatric, syndromic, and
adult WT GISTs, as summarized in Table 2. The initial study (Gill
et al., 2010b) identified SDHB-deficiency in the gastric epithelioid
GISTs from five CT cases and a single sporadic pediatric case, but
not in the spindle-cell, non-gastric GISTs from seven young adults
(age 21–29 years), or in three NF1-associated GISTs. Three SDHB-
deficient tumors were identified in a panel of 103 consecutive
sporadic adult GISTs. A second study (Gaal et al., 2011) confirmed
SDHB negativity in six additional CT cases, as well as four cases
with CSS. Five GISTs with KIT or PDGFRA mutations were all
SDHB-positive, as were 41 of 42 apparently sporadic cases with
unknown genotype. The sporadic adult SDHB-negative GISTs in
both studies were gastric tumors of epithelioid morphology. In a
larger study focused on GISTs with known KIT /PDGFRA geno-
type, SDH deficiency was investigated in 34 apparently sporadic
WT GISTs from pediatric and adult patients, along with 18 KIT
mutant GISTs and 5 NF1-associated GISTs (Janeway et al., 2011).
Germline SDHB-D sequence analysis identified only three cases
with pathogenic SDHB mutations and one case with an SDHC
mutation. No mutations were found in the SDH assembly factor
gene SDHAF2 in 42 WT cases. Of the remaining 30 WT cases, all 18
pediatric GISTs were SDHB-negative, while 8/12 of the adult cases
were SDHB-deficient. In contrast, 17/18 KIT mutant GISTs and
5 NF1-associated GISTs were positive for expression of the SDHB
subunit. The authors were also able to demonstrate reduction of
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SDH complex enzymatic activity (succinate-cytochrome c reduc-
tase) in two SDHB-negative GISTs, comparable to that seen in
an SDHB-mutant PGL. Notably, the adult WT sample set that
was analyzed had a significant age bias (mean of 37 years, median
27 years): of the four cases with positive SDHB staining, three of
those were over 55 years of age. In a subsequent study focused
on determining SDH status in a large group of gastric GISTs,
the authors arrived at a similar conclusion regarding the age-
dependence of SDH-deficient GISTs (Miettinen et al., 2011). In
a set of 756 gastric GISTs, 66 SDHB-negative GISTs were iden-
tified. When corrected for an age-specific selection bias in some
of their cases, the estimated frequency of SDHB-negative gastric
GISTs was 7.5%. Although SDHB-negative GISTs were found in
patients up to 77 years of age, again these cases as a whole were
much younger (mean 37 years, median 22 years) than the typical
spectrum of GIST patients, and had an overall female predomi-
nance (71%). No mutations were detected in this large group of
SDHB-negative GISTs, albeit only a limited panel of SDHB, SDHC,
and SDHD exons was analyzed. The study also included 378 non-
gastric GISTs, all of which were SDHB-positive. In another study
of GISTs with known kinase genotype (Doyle et al., 2012), 42%
of KIT /PDGFRA WT GISTs were negative for SDHB staining and
were notably all gastric GISTs with multinodular architecture and
epithelioid/mixed morphology. This result is interesting as it iden-
tifies a significant subset of SDH-positive adult WT GIST. In this
study the large group of 170 KIT - and 32 PDGFRA-mutant GISTs
were SDHB-positive. In summary, SDHB-deficiency is character-
istic of all tested CT- and CSS-related GISTs, pediatric WT GISTs,
and a minority of adult gastric GISTs, a population that is enriched
when considering tumor characteristics such as multi-focal nodu-
lar architecture, an epithelioid cell component, and kinase WT
status.
SDHAMUTATIONS ARE COMMON IN SDH-DEFICIENT GIST
Succinate dehydrogenase B-deficiency in PGL has generally been
connected to mutations in SDHB, SDHC, or SDHD (van Ned-
erveen et al., 2009; Gill et al., 2010a), and, as previously noted,
germline SDHB-D mutations were identified in most of the CSS
GIST cases (Pasini et al., 2008). In the studies cited above, only
a few SDHB-D mutations were described in sample sets total-
ing ∼140 cases of SDHB-negative GISTs. It should be noted that
not all cases were subject to SDHX gene sequencing, some of
the sequencing involved only a select panel of exons from SDHB,
SDHC, and SDHD, and only a few cases in one study (Janeway
et al., 2011) were examined for SDHA mutations. Sequencing
SDHA is a technical challenge, due to its large size (664 amino
acids encoded on 15 exons) as well as the presence of multiple
pseudogenes on chromosome 3 (SDHAP1, SDHAP2) and chro-
mosome 5 (SDHAP3). After the initial report of bi-allelic SDHA
inactivation in a PGL case (Burnichon et al., 2010), two reports
from the same group identified inactivating SDHA mutations
in four unselected WT GIST cases, first by whole-transcriptome
next-generation sequencing in two cases (Pantaleo et al., 2011a),
and subsequently in two additional cases by conventional Sanger
sequencing (Pantaleo et al., 2011c). The cases were WT non-
gastric GISTs from three adults (age 26–38 years) and one pediatric
patient, and in three of the four cases a germline nonsense or
Table 2 | SDHB-deficiency in GISTs.
Reference Sample set analyzed SDH-deficienta (%)
Gill et al. (2010b) 5 CT 100
1 Pediatric 100
7 Young adult 0
3 NF1-associated 0
104 Sporadic 3




Janeway et al. (2011) 2 SDHX mutants 100
18 Wild type pediatric 100
12 Wild type adult 67
18 KIT mutant 6
5 NF1-associated 0
Miettinen et al. (2011) 756 Gastric GISTs 8.7
378 Non-gastric GISTs 0
Doyle et al. (2012) 179 KIT mutant 0
32 PDGFRA-mutant 0
53 Wild type 42
aAs determined by lack of SDHB protein immunoreactivity.
missense mutation was identified accompanied by inactivation of
the second allele by LOH (one case) or a second heterozygous
mutation (two cases). In the other case germline DNA was not
available, however compound heterozygous missense mutations
were identified in the GIST. Subsequently, in a sample set of 11
SDHB-negative WT GIST cases (all gastric GISTs with an epithe-
lioid component), our group identified SDHA mutations in five
cases (45%), as well as a single case with an SDHC mutation (Belin-
sky et al., 2012). The cases with SDHA mutations were adults (age
33–52 years) with apparently sporadic cases of GIST. Germline
DNA was available in three cases, allowing us to demonstrate that
SDHA inactivation was due to a germline mutation (nonsense or
frameshift) plus an additional somatic point mutation (one case)
or loss of the WT allele in the GIST (two cases). In the other
two cases for which germline DNA was not available, sequencing
of the tumor revealed homozygous missense SDHA mutations,
presumably due to a germline point mutation accompanied by
allelic losses surrounding the chromosome 5p15 locus, identified
using high-density SNP copy-number arrays. Wagner et al. (2012)
investigating a larger sample set of 33 SDHB-deficient GIST, used
SDHA IHC to identify a subset of nine SDHA-deficient GISTs
(27%). These patients included five men and four women with
a median age of 38 years (range 19–53). The nine SDHA/SDHB-
deficient GISTs all harbored inactivating SDHA mutations: in six
cases DNA was available to demonstrate that one copy of the
gene was inactivated in the patient’s germline. SDHA mutations
have been reported in nine additional SDHA/B-deficient cases
(Dwight et al., 2012; Italiano et al., 2012; Oudijk et al., 2012),
adding to the perception of the utility of SDHA IHC in identify-
ing cases with SDHA mutations. However, in a very recent study
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(Miettinen et al., 2012), three cases were reported in which tumors
were SDHB-negative/SDHA-positive by IHC, yet harbored muta-
tions in the SDHA gene. We have noted this phenomenon in one
of our own cases, as shown in Figure 1. SDHB staining is absent in
the tumor tissue of all three WT GISTs (Figures 1C,G,K), while the
mutant GIST (Figure 1O) and normal cell compartments within
the WT sections stain positive. The kinase WT GIST represented
in the top panels has a homozygous, truncating SDHA mutation
(c.457-3_c457delCAG, p.L153Kfs∗71). This tissue as expected is
immunonegative for SDHA (Figure 1D) as well as for SDHB.
However, the second WT tumor, with compound heterozygous
SDHA missense mutations (c.818C>T, p.T2731I; c1357G>A,
p.G453R) stains positive for SDHA (Figure 1H), as does the third
WT case, in which no SDHX mutations were detected (Figure 1L).
The three cases reported by Miettinen et al. all possessed SDHA
missense mutations, including the T273I mutation described in
our case and two novel mutations (p.R188W, p.A454E). All these
mutations fall within the FAD-binding domain of the SDHA
flavoprotein and are predicted to be deleterious using in silico
approaches based on sequence conservation and protein structure
and function (Kumar et al., 2009; Adzhubei et al., 2010). These
observations suggest that although SDHA-negative IHC is predic-
tive of SDHA mutations, some missense mutations may escape
detection using IHC alone.
To date, SDHA mutations have been reported in 37 GIST cases
(Korpershoek et al., 2011; Pantaleo et al., 2011c; Belinsky et al.,
2012; Dwight et al., 2012; Italiano et al., 2012; Miettinen et al., 2012;
Wagner et al., 2012). In the five largest series reporting SDHA gene
sequencing in SDHB-deficient GISTs (Belinsky et al., 2012; Dwight
et al., 2012; Miettinen et al., 2012; Oudijk et al., 2012; Wagner et al.,
2012), the frequency of reported SDHA mutations is∼31%. While
it is important to consider that the overall frequency of SDHA
mutations in GIST is low given that SDH deficiency is seen in only
∼8% of all gastric GISTs (Miettinen et al., 2011), mutations in
the SDHA subunit alone may be as common as mutations in all
other subunits combined (Miettinen et al., 2012). This observa-
tion is perhaps not surprising given the relative size of the SDHA
gene as compared to the other subunit genes, however this pat-
tern is not seen in PGLs and PHEO, where SDHA mutations and
allelic losses are rare as compared to those reported for SDHB and
SDHC subunit genes (Burnichon et al., 2010; Korpershoek et al.,
2011; Welander et al., 2011). This may point to a lack of penetrance
of SDHA mutations in initiating PGL/PHEO neoplasms. For the
reported SDHA-mutated GISTs, all originated in the stomach, gen-
erally with epithelioid/mixed morphology (one spindle-cell tumor
was reported). Of the 27 cases for which individual patient data
was reported, 17 (63%) were female, with a median age of 38 years
(range 14–53). This agrees well with the summary reporting by
FIGURE 1 | Immunohistochemical analysis of KIT, IGF1R, SDHB, and
SDHA expression in WT and KIT mutant GISTs. Primary antibodies used
include KIT (Dako), IGF1R (Cell Signaling), SDHB (Abcam), and SDHA (Abcam).
Positive KIT staining is evident throughout tumor tissue in all cases (A,E,I,M).
Strong staining for IGF1R is seen in the WT GISTs (B,F,J) but not in the KIT
mutant GIST (N). SDHB staining is evident in the mutant GIST (O) and in the
adjacent normal tissue and epithelial cells in the WT cases, but absent in the
tumor tissue (C,G,K). SDHA staining is absent in an SDHB-deficient GIST
with a truncating SDHA mutation (D). Positive SDHA staining is evident in an
SDHB-deficient GIST harboring compound heterozygous missense SDHA
mutations (H), and in an SDHB-deficient GIST with no identified SDH
mutations (L) as well as in the mutant GIST (P). See text for more detailed
mutation descriptions. GIST cases have been previously reported (Belinsky
et al., 2012): (A–D), case 2; (E–H), case 1; (I–L), case 10; (M–P), case 21.
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Miettinen et al. (2012) for 36 SDHA-deficient cases, in which 64%
of cases were female with a median age of presentation of 34 years.
Altogether 25 distinct SDHA mutations have been identified in
GIST cases, as summarized in Figure 2. As can be seen from the
figure, missense, nonsense, and splice-site mutations, along with
small deletions, have been identified within or adjacent to the
coding region of 12 of the 15 exons of the gene. The one notable
hotspot is the R31∗ mutation in exon 2, representing 15/42 or
∼36% of the occurrences. In most cases bi-allelic inactivation was
detected, generally due to an LOH event, although in several cases
compound heterozygous SDHA mutations were reported (Panta-
leo et al., 2011c; Belinsky et al., 2012; Dwight et al., 2012; Wagner
et al., 2012). Notably, in a few cases where a heterozygous SDHA
mutation was reported, a second genetic event was not detected
(Dwight et al., 2012; Italiano et al., 2012; Oudijk et al., 2012; Wag-
ner et al., 2012), leaving open the possibility that only one allele
was inactivated, or that some other mechanism, genetic or epige-
netic, was responsible for bi-allelic inactivation. Along these lines,
in our own study we reported one case with a heterozygous somatic
mutation in the SDHC gene (p.Gly75Asp) that was fully homozy-
gous in cDNA (Belinsky et al., 2012). In this one case, we were able
to provide convincing evidence for silencing of the remaining WT
allele through hyper-methylation of a CpG island present at the 5′
end of the gene (Huang et al., 2009).
DISTINCT PATTERNS OF CYTOGENETIC PROGRESSION IN
SDH-DEFICIENT GIST
Although GISTs are generally considered cytogenetically non-
complex (Yang et al., 2008), the oncogenetic progression of spo-
radic GISTs with activating kinase mutations is usually accom-
panied by characteristic, large-scale chromosomal copy-number
aberrations (CNAs). In primary GISTs the mean number of CNAs
detected is∼7 per tumor, with losses outnumbering gains by∼2.5-
fold (Wozniak et al., 2007). Loss of all or part of chromosome
14q is a frequent (∼70%) and apparently early event in GIST,
seen in both benign and malignant tumors (el-Rifai et al., 1996;
Breiner et al., 2000; Debiec-Rychter et al., 2001; Gunawan et al.,
2007). Early studies, combining cytogenetic, chromosomal com-
parative genomic hybridization (CGH), and microsatellite LOH
approaches, delineated specific regions of CNA on 14q, includ-
ing 14q11–q12, 14q22–q23, and 14q24.3 (El-Rifai et al., 2000b;
Debiec-Rychter et al., 2001). Copy-number losses on chromosome
22q and 1p are also common, seen in about 50% of GISTs (El-Rifai
et al., 2000a; Chen et al., 2004; Gunawan et al., 2007). Chromo-
some 22q deletions were targeted in additional studies to identify
common deleted regions at 22q13.3 and 22q11.22 (Lasota et al.,
2005) and at 22q12.2 and 22q12.1 (Pylkkanen et al., 2003). These
CNAs on chromosomes 1, 14, and 22 seem to occur in tumors
with either KIT or PDGFRA mutations (Heinrich et al., 2003;
Assamaki et al., 2007; Wozniak et al., 2007), but exhibit distinctive
tumor site-dependence, with 14q losses more common in gastric
GIST, while 1p (and 15q) losses are seen more often in intestinal
GISTs (Gunawan et al., 2004; Wozniak et al., 2007). The pattern of
aberrations in a large group of 116 gastric and 87 intestinal GISTs
was used to generate an “oncogenic tree model” describing the
cytogenetic evolution of these GISTs. This model identified three
pathways of cytogenetic evolution (e.g., pathways initiated by 14q,
1p, or 22q loss), with distinctive characteristics regarding tumor-
site, genomic complexity, and prognosis (Gunawan et al., 2007). In
addition to these common changes, copy-number losses have also
been described with significant frequency on chromosomes 9, 13q,
10q, and 21q (El-Rifai et al., 2000a; Chen et al., 2004; Wozniak et al.,
2007; Belinsky et al., 2009). Some of these chromosomal losses
(e.g., 9p and 9q, 13q, and 15q) are more often seen in advanced
or metastatic GIST and may have value as prognostic markers
(El-Rifai et al., 2000a; Kim et al., 2000; Gunawan et al., 2004; Woz-
niak et al., 2007). Similarly, regions of chromosomal copy-number
gain, specifically gains in chromosome 5 and 8, while they occur
less frequently overall in GIST, seem to be characteristic of more
advanced GISTs (El-Rifai et al., 2000a; Debiec-Rychter et al., 2001;
Assamaki et al., 2007). Array-CGH studies of fairly large sample
sets of KIT and PDGFRA-mutated tumors have refined the mini-
mum overlapping regions commonly deleted in GISTs, including
1p, 14q, 15q, and 22q, along with some less common regions of
FIGURE 2 | Distribution of reported SDHA gene mutations in GIST.
Boxed numbers indicate exons, connecting lines represent introns (not
drawn to scale), U = 5′, 3′ untranslated regions. Mutations are annotated
at the cDNA and protein level, followed by the number of reported cases
in parentheses. *Indicates stop codon. #Mutations reported in
paraganglioma.
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copy-number loss and gain (Assamaki et al., 2007; Wozniak et al.,
2007). More recently, the combination of high-resolution genome-
wide copy-number analyses with global gene expression data has
been used to develop integrated molecular portraits of the onco-
genesis of KIT /PDGFRA-mutated GIST (Astolfi et al., 2010; Yang
et al., 2010; Ylipaa et al., 2011).
The SDH-deficient gastric GISTs found in children, either spo-
radically or in the context of CT, appear to lack the characteristic
chromosomal losses of mutant GIST, and generally are less cyto-
genetically complex than the mutant GISTs that comprise the
majority of adult sporadic cases. In an early report analyzing GISTs
from three pediatric/young adult female CT cases, CGH analysis
identified one region of chromosome loss (13q32–q34) in one of
the three GISTs, along with 13 regions of CN gain/amplification
in the three tumors (Agaimy et al., 2007). In a larger CGH study
of 31 GISTs (plus 10 associated tumors, mainly PGLs) from 28
CT patients (including 13 pediatric cases), fully 55% of the GISTs
showed no significant CGH changes (Table 3) (Matyakhina et al.,
2007). Losses at 14q or 22q were identified in only one GIST case
each. The 31 GISTs analyzed manifested a mean of only ∼1.1
CNAs per tumor (range 0–6). Interestingly, recurrent losses were
identified on chromosome 1q (four cases) or 1p (four cases), or
both (two cases). While the SDHB gene (1p36.1–p35) and SDHC
gene (1q23.3) reside on chromosome 1, involvement of these genes
in the reported CT cases is unclear, as no mutations were identi-
fied in SDHA-D genes in this study. In a study of 13 pediatric
GIST cases, including two CT patients, low-density SNP arrays
were used to identify chromosomal CNAs and regions of LOH
(Table 3) (Janeway et al., 2007). These tumors showed even less
cytogenetic progression, with 10/13 (77%) showing no detectable
changes. Only seven regions of CNA or LOH were reported in the
13 cases, despite the fact that the sample set included high risk
or recurrent/metastatic pediatric GIST. In the case of adult WT
GIST, a few cases have been reported with significant cytogenetic
progression (Assamaki et al., 2007; Belinsky et al., 2009). How-
ever, in our recent study of 16 SDH -deficient GIST from 11 cases
(including 3 CT cases), most of which were sporadic adult cases,
a total of 30 CNAs or LOH events were identified (∼1.8/samples).
No 14q/22q losses were seen at all, and only one case exhibited
chromosome 1p loss. Recurrent losses or LOH events at chro-
mosome 5p (five cases) were generally found in the cases with
SDHA coding-region mutations (Table 3). Similarly, allelic LOH
events were documented in association with germline SDHB-D
mutations in CSS patients (McWhinney et al., 2007; Pasini and
Stratakis, 2009), and more recently in additional SDHA-mutated
GISTs (Pantaleo et al., 2011c; Dwight et al., 2012; Oudijk et al.,
2012; Wagner et al., 2012). As mentioned previously, the SDHB-
deficient GISTs seen in young sporadic and CT cases generally
exhibit an indolent yet unpredictable clinical course (Miettinen
et al., 2005a; Agaimy et al., 2007; Agaram et al., 2008a; Zhang
et al., 2010). It is tempting to speculate that the lack of cytoge-
netic progression exhibited by SDH-deficient GISTs may in part
account for their more indolent clinical behavior in comparison
to kinase-mutant GIST. To this point it is interesting to note that
in the large CGH study of CT patients, metastatic lesions showed a
trend toward greater cytogenetic progression than benign tumors
(Stratakis and Carney, 2009). To reach a better understanding of
the clinical behavior of WT GIST may require further investiga-
tion of the molecular genetic, cytogenetic, and epigenetic changes
in these tumors. To this point, a very recent report describes
the epigenomic divergence between SDH-deficient WT GIST and
GISTs with activating kinase mutations (Killian et al., 2013). In
this study, a set of 24 SDH-deficient GISTs, again with relatively
stable genomes, was found to exhibit a pattern of global DNA
Table 3 | Reported chromosomal aberrations in wild type GIST.
Reference Sample set analyzed Methodology Notable findings
Matyakhina
et al. (2007)
31 GISTs from 28 CT
casesa
CGH No changes reported in 17 GISTs (55%)
Frequent 1p and/or 1q losses (six cases each, 19%)
Additional changes reported in ≤2 cases:
Gains: 1p11, 1q, 4p11–p15, 5p11–q11, 8q33–q34, 12p11–p12, 12q13–q22, 15q14-qter
Losses: 3q13–qter, 6q15–qter, 10q22–qter, 11p, 14q23–qter, 16q, 17p, 17q, 22q
Janeway et al.
(2007)
13 Pediatric GISTsb SNP array No changes reported in 10 GISTs (77%)
One case with 5p gain only
One case with copy-number neutral 11q LOH only




GISTs from 11 casesc
SNP array No changes reported in two cases (18%)
5p Losses/LOH in five cases (45%)
1q Gains in three cases (27%)
Additional changes reported in ≤2 cases:
Gains: 5p15.33.q35.3, 11p15.5.p15.3, 11q12.3.q22.3
Losses: 1p36.33.p12, 10p15.3.126.3, 11q22.3.q25, 13q11.q34, 17p12, 19p12, 22q11.23
aIncludes 13 pediatric cases.
bIncludes two CT cases.
cIncludes three CT cases (one pediatric, two adult).
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hyper-methylation, in comparison to 39 RTK mutant GISTs. This
pattern of epigenomic divergence was also seen in SDH-deficient
PGL/PHEO, as well as in gliomas exhibiting defects in another
Krebs cycle enzyme, isocitrate dehydrogenase (IDH), establish-
ing a link between Krebs cycle metabolism and maintenance of
methylation patterns in genomic DNA.
EXPRESSION OF IGF1R IN SDH-DEFICIENT WT GISTs
As mentioned above, the great majority of pediatric GISTs lack
mutations in either KIT or PDGFRA, and a significant subset of
adult GIST is also WT for these RTKs. However, most pediatric and
WT GISTs express KIT (Figures 1A,E,I), and several studies sug-
gest that the KIT receptor and downstream signaling pathways are
activated in pediatric GISTs (Janeway et al., 2007; Agaram et al.,
2008a). Two early studies from the same group endeavored to
characterize pediatric GISTs using global gene expression profil-
ing (Prakash et al., 2005; Agaram et al., 2008a). In the initial study,
the gene expression patterns of seven gastric GISTs from two pedi-
atric WT cases and two young adults (one WT, one mutant) were
compared to 10 gastric GISTs from adults (one WT, nine mutant).
Unsupervised clustering approaches identified distinct transcrip-
tional profiles for the GISTs from the pediatric/young adult cases,
which with one exception clustered separately from the adult cases.
This analysis identified 385 differentially expressed genes between
the two groups (Prakash et al., 2005). In the second study, a larger
group of 13 gastric tumor nodules, all WT, from 8 pediatric WT
cases was analyzed (several of these cases were analyzed in the first
report). The pediatric group included two CT cases. Two compar-
isons were made, first to 5 WT GISTs from adult patients, then
to a set of 19 primary GISTs from adults of mixed genotype (3
WT, 4 PDGFRA-mutants, 12 KIT mutants), but matched as to
gastric location. In both analyses the pediatric and adult cases
formed distinct clusters based on their transcriptional profiles,
with the notable exception of three young adult cases (<30 years)
with clinico-pathological characteristics more in keeping with the
pediatric GISTs (e.g., multi-focality, epithelioid cell morphology,
indolent clinical course). These three tumors (two WT, one KIT
exon 11 mutant) clustered instead with the pediatric WT tumors.
An intersection of genes in common to the two analyses identified
814 differentially expressed genes in the pediatric group (Agaram
et al., 2008a). Intriguingly, of the genes reported in the two stud-
ies, the only gene in common was another RTK, the insulin-like
growth factor receptor (IGF1R), which was expressed 11–14 fold
higher in the pediatric GIST samples. In 2008 we reported that
IGF1R was over-expressed at the protein and RNA level in several
adult WT GIST samples, in comparison to mutant GISTs (Tarn
et al., 2008). We subsequently confirmed this observation in a
larger set of mainly adult WT GISTs (Belinsky et al., 2008), while
Janeway et al. (2010) reported the over-expression of IGF1R pro-
tein in pediatric WT GISTs. In these studies, the levels of total
and phosphorylated IGF1R protein in WT GISTs do not corre-
spond well, perhaps due to cross-reactivity of the phospho-IGF1R
antibody with the phosphorylated insulin receptor (Janeway et al.,
2010). The over-expression of IGF1R RNA is not usually accom-
panied by amplification of the gene (Pantaleo et al., 2009; Janeway
et al., 2010; Chou et al., 2012). Instead, the high level of IGF1R
expression in pediatric GISTs and a subset of the WT GISTs found
in adults may be part of a transcriptional profile inherent to the
cell of origin of these distinctive GISTs. Pantaleo et al. (2011b)
recently reported an expression profiling study of four gastric WT
GISTs from young adult cases, along with 26 mutant GISTs, and
a meta-analysis of these expression profiles versus published data
for murine ICCs. Interestingly, the expression data from human
mutant GISTs and murine ICC clustered together, and separate
from the WT tumors. An analysis of the top 448 differentially
expressed genes (with P < 0.001) with respect to gene ontology
and tissue expression revealed a pattern of expression within the
WT tumors of genes related to neurogenesis functions and derived
from neural tissues. IGF1R was again among these genes, and the
over-expression of IGF1R, as well as that of several other neural
markers, was validated in the study. This data adds support to the
proposal that WT GISTs may derive from IGF1R-expressing ICC
progenitor cells, rather than mature ICCs (Lorincz et al., 2008).
With the increased emphasis on the role of SDH deficiency
and SDHX mutations in pediatric, syndromic, and adult WT
GISTs, several recent studies have looked at the correlation between
IGF1R expression and SDH deficiency. In our own study, 11
of 12 WT GIST samples were SDHB-negative: all these tumors
over-expressed IGF1R at both the RNA and protein level (see for
illustration Figures 1B,F,J as compared to Figure 1N). The one
SDHB-positive WT tumor expressed IGF1R at comparable lev-
els to the mutant GISTs in the study (Belinsky et al., 2012). Chou
et al. (2012) recently reported a study of eight SDH-deficient GISTs
along with 3 NF1-related and 40 unselected tumors (35 mutant, 5
WT). Two of the unselected WT GISTs were also SDHB-negative;
these 10 SDHB-negative tumors all expressed high levels of IGF1R
as evaluated by IHC. In contrast, the remaining WT GISTs, along
with the 3 NF1-derived and 35 mutant tumors, expressed the
receptor at low levels. The strong correlation of IGF1R expres-
sion and SDH status has been confirmed with a large IHC study
of 1078 GIST, including 705 gastric GISTs and 373 originating in
the intestine (Lasota et al., 2012). Eighty SDHB-negative GISTs, all
originating in the stomach, were identified: of these, 71 were high
IGF1R-expressing tumors. Of 625 SDH-positive gastric GISTs,
only 9 expressed significant levels of IGF1R. All intestinal GISTs
were SDHB-positive and expressed low IGF1R levels. From these
studies it seems clear that IGF1R over-expression is a further defin-
ing characteristic of the SDH-deficient WT gastric tumors found
mainly in children and in younger adults.
THERAPEUTIC OPPORTUNITIES FOR WT SDH-DEFICIENT
PEDIATRIC AND ADULT GISTs
Wild type SDH-deficient GISTs constitute the great majority of
pediatric cases and a significant percentage of gastric occurrences
in younger adults. It is reasonable to expect that the targeted thera-
pies that have proven effective in mutant GISTs may prove inferior
as systemic therapy in tumors lacking gain-of-function kinase dri-
vers. Historical data in patients with advanced GIST suggests that
median overall survival (OS) without TKI therapy is 20 months
and that cytotoxic chemotherapy is not effective (Gold et al., 2007).
Standard approved therapies for GIST now consist of the TKIs
IM and sunitinib. Therapy with IM provides response rates of
∼72% and improved median OS of >60 months in adult patients
with GISTs harboring KIT exon 11 mutations, while WT patients
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exhibited response rates of only∼45%,and OS less than 50 months
(Heinrich et al., 2008b). In adults with metastatic GIST that had
progressed on IM, clinical benefit of sunitinib was superior for
patients with WT versus KIT exon 11 mutations (56 versus 34%),
however no objective responses were documented (Heinrich et al.,
2008a). For children with GIST, of which the great majority are WT
tumors, the primary treatment remains surgical resection of the
tumor with testing and removal of involved lymph nodes, followed
by postoperative surveillance using CT or MRI scans (Janeway and
Pappo, 2012). There have been recent reports evaluating the use
of IM and sunitinib in pediatric GIST patients (Cypriano et al.,
2004; Hayashi et al., 2005; Kuroiwa et al., 2005; Prakash et al., 2005;
Sauseng et al., 2007; Agaram et al., 2008a; Bond et al., 2008; Dele-
marre et al., 2008; Janeway et al., 2009). These studies revealed only
one documented response to IM in a 14-year-old male with CT
(Delemarre et al., 2008) and additional instances of stable disease
for periods of 6–16 months. Sunitinib appears to be slightly more
effective. Partial response (PR) has been reported in two young
patients (ages 10 and 18 years) with WT GIST but the more typ-
ical response to sunitinib in pediatric patients with WT GIST is
SD (Agaram et al., 2008a; Janeway et al., 2009). However, time to
progression on sunitinib was longer than time to progression for
previous IM in most of these patients (Janeway et al., 2009).
As described in several recent reviews, other TKIs are being
tested in clinical trials for efficacy as systemic therapy in GIST
patients who progress or show intolerance to IM/sunitinib
(Demetri, 2011; Kim and Zalupski, 2011). These agents differ in
properties such as mode of binding, kinase selectivity, and other
biological properties, some of which may prove advantageous in
the treatment of WT pediatric and adult GISTs. For example,
masitinib (AB Science), an oral TKI with selectivity for KIT and
PDGFRA, inhibits WT KIT at sub-micromolar concentrations in
cell-based assays (Dubreuil et al., 2009). In a Phase II trial testing
masitinib as front-line therapy for 30 patients, including 3 WT
cases, masitinib treatment resulted in CR/PR in 16 patients and
stable disease in 13 others; the mutation-dependent response has
not yet been reported (Le Cesne et al., 2010). Other RTKs exhibit-
ing greater in vitro activity against WT KIT than IM, including
dasatinib (Sprycel, Bristol–Meyers Squibb), sorafenib (Nexavar,
Bayer), and nilotinib (Tasigna, Novartis) (Agaram et al., 2008a)
have been investigated, but again much of the data on benefit has
not been correlated with mutational status.
With the significant progress made during the last few years in
elucidating the unique biology of WT GISTs (both pediatric and
adult), novel targets have come to light, which may have poten-
tial therapeutic implications. First, as detailed above, IGF1R is
over-expressed in the vast majority of SDH-deficient WT GISTs,
including pediatric cases, although some WT GISTs express the
receptor at levels comparable to KIT /PDGRA mutant tumors
(Corless et al., 2009). With respect to IGF1R and its downstream
signaling molecules, our group has showed that the small molecule
TKI, NVP-AEW541 (Novartis), which has activity against IGF1R,
can lead to cytotoxicity in mutant GIST cell lines, via AKT and
MAPK signaling that is independent from KIT signaling. Similar
findings were observed when IGF1R levels were impaired using
targeted siRNAs. Additive effects were observed by combining
NVP-AEW541 and imatinib, suggesting a potential therapeutic
benefit in targeting IGF1R in GISTs that are unresponsive to ima-
tinib, including GISTs that overexpress IGF1R (Tarn et al., 2008).
It should be noted however that these studies were performed
in KIT mutant cell lines. Fortunately, a number of agents tar-
geting IGF1R were already being developed and tested in solid
tumors, allowing for rapid translation from the bench findings to
ongoing clinical trials in GIST. A recent report published the first
anti-IGF1R-targeted therapy in a patient with NF1-associated WT
GIST (Day et al., 2011). This patient progressed within 4 weeks
of treatment with the anti-IGF1R fully humanized monoclonal
antibody R1507 (Roche). NF1-associated WT GISTs, as noted
above, are generally positive for SDHB expression and express
low levels of IGF1R (Gill et al., 2010b; Janeway et al., 2011; Chou
et al., 2012). In the reported case, it was determined that the
tumor had very low expression of IGF1R, a plausible explana-
tion for the lack of efficacy in this patient. An ongoing phase
II trial is testing the IGF1R inhibitor linsitinib (OSI-906, Astel-
las, NCT01560260) in GIST patients that lack mutations in KIT,
PDGFRA, and BRAF.
The more recent findings that many WT GISTs have defi-
ciencies in SDH suggest the possibility of exploiting a second
target pathway, namely the hypoxic response to SDH complex
inactivation that is facilitated by HIF transcriptional factors. The
SDH, anchored in the mitochondrial inner membrane, converts
succinate to fumarate as part of the TCA cycle, and couples
this oxidation reaction to the reduction of Coenzyme Q (CoQ,
ubiquinone) (Figure 3). When SDH is inactivated by SDH muta-
tion or other mechanisms, succinate accumulates in the mitochon-
dria and is transported to the cytosol, where it has been shown
to inhibit the enzyme prolyl 4-hydroxylase (PHD) (Selak et al.,
2005). PHD belongs to a super-family of enzymes that couple
hydroxylation of their substrate with oxidative decarboxylation
of alpha-ketoglutarate to succinate (Schofield and Zhang, 1999;
Ozer and Bruick, 2007). In normoxic conditions, PHD catalyzes
the hydroxylation of HIFα, which facilitates binding to the VHL
(von Hippel–Lindau) gene product and targeting of the HIFα for
ubiquitination and proteasomal degradation. Under hypoxic con-
ditions PHD activity is limited by oxygen deprivation allowing
HIFα to accumulate (Pugh and Ratcliffe, 2003), while in pseudo-
hypoxia induced by SDH deficiency, increased cytosolic levels of
succinate lead to product inhibition of PHD (Selak et al., 2005).
Stabilized HIFα translocates to the nucleus where it dimerizes with
HIFβ subunits, and activates transcriptional programs promot-
ing angiogenesis, glycolysis, and cell proliferation (Cervera et al.,
2008).
Succinate dehydrogenase mutations leading to the activation of
a pseudohypoxic response, and in particular up-regulation of the
vascular endothelial growth factor (VEGF) have been described in
other tumors (PGL and renal cell carcinoma) (Ricketts et al., 2008;
Pasini and Stratakis, 2009; Favier et al., 2012; Linehan and Rick-
etts, 2012). Consistent with this mechanism, WT GISTs have been
shown to have higher VEGF expression than their KIT/PDGFR-
mutant counterparts (Antonescu et al., 2004). This suggests that
targeting this pathway may be of interest and is supported by the
limited data on sunitinib, which is a potent inhibitor of VEGFR
(Demetri, 2011). In addition, a phase I study of nilotinib, which
has activity against BCR-ABL, discoidin domain receptor (DDR),
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FIGURE 3 | Induction of the pseudohypoxic response in
SDH-deficient GIST. SDH, composed of the catalytic subunit (SDHA
and SDHB) anchored to the inner mitochondrial membrane through
subunits SDHC and SDHD, oxidizes succinate to fumarate as part of the
tricarboxylic acid (TCA) cycle and couples this oxidation to the reduction
of Coenzyme Q (CoQ, ubiquinone) as complex II of the electron
transport chain (not shown). Inactivation of SDH via SDHX gene
mutation or other mechanisms leads to succinate accumulation in the
mitochondria and subsequent export to the cytosol via metabolite
transporters (not shown). Increased cytosolic succinate levels act to
stabilize one of three HIFα subunits (HIF1α is shown for simplicity) via
product inhibition of PHD-mediated hydroxylation of HIF1α, which skirts
the VHL-mediated targeting of HIF1α for degradation. Stabilization and
nuclear translocation of HIF1α leads to formation of the heterodimeric
HIF transcription factor with constitutively expressed nuclear-located
HIF1β, and induction of the pseudohypoxic response.
KIT, PDGFR, and colony-stimulating factor receptor-1 (CSF-1R)
tyrosine kinases (Blay and von Mehren, 2011), showed remark-
able disease stabilization, following failure of IM and sunitinib, in
two younger adult women (ages 27, 39 years) whose GISTs har-
bored SDHA mutations (Pantaleo et al., 2012). These findings are
intriguing since nilotinib had been shown to perform no better
than imatinib in the majority of GIST patients enrolled on trial
(CAMN107A2201-ENESTG3 and CAMN107G2301-ENESTG1)
(Cauchi et al., 2012). These authors speculate that potential off-
target effects of nilotinib could be targeting the pseudohypoxic
response caused by the SDHA mutation. More studies examin-
ing the role of nilotinib on the treatment of SDH-deficient GISTs
are warranted. Other RTKs with dual activity against KIT and
the VEGF receptors include sorafenib, vatalanib, motesanib, and
regorafenib, which was recently FDA approved for treatment of
GISTs refractory to standard therapy in 2013 (Kim and Zalupski,
2011). The monoclonal antibody bevacizumab is another agent
that targets angiogenesis, specifically by binding circulating VEGF.
Finally, other agents that specifically target HIF1α level and/or sig-
naling have been reported in various pre-clinical and clinical stages
(Tennant et al., 2010).
CONCLUSION
Gastrointestinal stromal tumor, once known as a chemotherapy
refractory sarcoma, has become the poster child for targeted ther-
apy. While the progress made in the clinic with TKIs has been
profound, patients whose GISTs are not well controlled have
become the focus of ongoing investigations. The rare cases of
GISTs in the pediatric population were a conundrum, as they did
not have the anticipated response to IM. We also noted 10–15%
of patients in the adult population with metastatic disease who
progressed rapidly within 6 months of IM therapy, some of whom
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had WT GISTs. Studies of these refractory pediatric patients have
found parallels in the group of adult patients whose tumors do not
have activating kinase mutations. It is now clear that differentiat-
ing these two groups based on the age of diagnosis is unwarranted.
Research over the past decade, reviewed above, has led to the reclas-
sification of some of these WT GISTs as SDH-deficient GISTs,
whose hallmarks include gastric site of origin that is often multi-
focal with lymph node involvement and with epithelioid histology.
Future trials of GIST patients will need to consider these patients
as biologically distinct and requiring strategies not focused on KIT
and PDGFRA. In addition, this group of patients is now also one
in whom genetic counseling must be considered given the risk of
the familial CSS and its associated risk for malignant PGLs.
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